Screener
NovoCure NVCR Balance Sheet Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $96.73M-71.7% | $93.7M-37.4% | $87.53M-31.2% | $93.55M-42.9% | $342.12M+84.5% | ||
| $40.61M+3.8% | $42.22M+5.0% | $43.46M+10.1% | $41.11M+17.2% | $39.1M0.0% | ||
| $673.52M-43.9% | $638.52M-41.1% | $631.66M-42.0% | $646.73M-41.6% | $1.2B+9.5% | ||
| $72.67M-9.1% | $75.37M-6.2% | $76.28M-4.2% | $77.61M-0.1% | $79.98M+9.2% | ||
| $155.19M-3.8% | $156.67M-3.6% | $156.26M-2.0% | $157.6M+17.4% | $161.34M+27.3% | ||
| $828.71M-39.1% | $795.19M-36.2% | $787.93M-36.9% | $804.33M-35.2% | $1.36B+11.4% | ||
| $145.92M+22.7% | $130.73M+26.1% | $127.24M+33.8% | $122.23M+16.3% | $118.92M+30.2% | ||
| $25M— | —— | —— | —— | —— | ||
| $270.66M-65.1% | $220.71M-70.6% | $217.58M-70.7% | $223.23M-70.5% | $776.01M+5.6% | ||
| $207.44M-14.9% | $236.39M+61.0% | $239.63M+66.9% | $240.63M+93.7% | $243.86M+93.2% | ||
| $478.1M-53.1% | $457.1M-49.0% | $457.21M-48.4% | $463.86M-47.3% | $1.02B+18.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$1.39B-9.6% | -$1.38B-12.1% | -$1.36B-14.6% | -$1.29B-11.8% | -$1.27B-16.3% | ||
| $350.61M+2.7% | $338.09M-3.2% | $330.72M-8.6% | $340.47M-5.5% | $341.33M-5.4% | ||
| $828.71M-39.1% | $795.19M-36.2% | $787.93M-36.9% | $804.33M-35.2% | $1.36B+11.4% |
FAQ
- What are NovoCure's total assets?
- NovoCure (NVCR) holds $828.7M in total assets, down 39.1% year over year.
- How much debt does NovoCure have?
- NovoCure carries $60.2M in total debt against $350.6M of shareholders' equity, a debt-to-equity ratio of 0.17.
- How much cash does NovoCure have?
- NovoCure holds $96.7M in cash and equivalents.
- Can NovoCure cover its short-term obligations?
- Its current ratio is 2.49 — current assets exceed current liabilities.
- Where does NovoCure's balance sheet data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
